Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death

Journal of Molecular and Cellular Cardiology

Volumn 75, Issue , 2014, Pages 141-151

  Yoshida, Tadashi ^a   Friehs, Ingeborg ^b   Mummidi, Srinivas ^c   del Nido, Pedro J ^b   Addulnour Nakhoul, Solange ^a,d   Delafontaine, Patrice ^a   Valente, Anthony J ^b   Chandrasekar, Bysani ^a,d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiac failure; Cyclical stretch; Inflammation; Interleukins; Myocardial hypertrophy

Indexed keywords

BINDING PROTEIN; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 18 RECEPTOR BETA; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN-18 BINDING PROTEIN; MESSENGER RNA; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DISEASE COURSE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; IN VITRO STUDY; MUSCLE HYPERTROPHY; NONHUMAN; RABBIT; THORACIC AORTA; ANIMAL; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; ENDOTHELIUM CELL; GENETICS; HUMAN; MALE; MECHANICAL STRESS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PRESSURE;

ORYCTOLAGUS CUNICULUS;

ANIMALS; CARDIOMEGALY; CELL DEATH; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; MALE; MOLECULAR SEQUENCE DATA; MYOCYTES, CARDIAC; PRESSURE; RABBITS; RECEPTORS, INTERLEUKIN-18; RNA, MESSENGER; STRESS, MECHANICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922727583     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.07.007     Document Type: Article

References (41)

1. Chandrasekar B., Mummidi S., Claycomb W.C., Mestril R., Nemer M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem Feb 11 2005, 280(6):4553-4567.
2. Fix C., Bingham K., Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine Jan 2011, 53(1):19-28.
3. Siddesha J.M., Valente A.J., Sakamuri S.S., Gardner J.D., Delafontaine P., Noda M., et al. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J Cell Physiol Jul 2014, 229(7):845-855.
4. Valente A.J., Sakamuri S.S., Siddesha J.M., Yoshida T., Gardner J.D., Prabhu R., et al. TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation. Cell Signal Nov 2013, 25(11):2176-2184.
5. Chandrasekar B., Vemula K., Surabhi R.M., Li-Weber M., Owen-Schaub L.B., Jensen L.E., et al. Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem May 7 2004, 279(19):20221-20233.
6. Chandrasekar B., Mummidi S., Mahimainathan L., Patel D.N., Bailey S.R., Imam S.Z., et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem Jun 2 2006, 281(22):15099-15109.
7. Reddy V.S., Valente A.J., Delafontaine P., Chandrasekar B. Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. J Cell Physiol Dec 2011, 226(12):3303-3315.
8. Woldbaek P.R., Sande J.B., Stromme T.A., Lunde P.K., Djurovic S., Lyberg T., et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol Aug 2005, 289(2):H708-H714.
9. Platis A., Yu Q., Moore D., Khojeini E., Tsau P., Larson D. The effect of daily administration of IL-18 on cardiac structure and function. Perfusion Jul 2008, 23(4):237-242.
10. Colston J.T., Boylston W.H., Feldman M.D., Jenkinson C.P., de la Rosa S.D., Barton A., et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun Mar 9 2007, 354(2):552-558.
11. Mallat Z., Heymes C., Corbaz A., Logeart D., Alouani S., Cohen-Solal A., et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J Nov 2004, 18(14):1752-1754.
12. Yu Q., Vazquez R., Khojeini E.V., Patel C., Venkataramani R., Larson D.F. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol Jul 2009, 297(1):H76-H85.
13. Kim S.H., Eisenstein M., Reznikov L., Fantuzzi G., Novick D., Rubinstein M., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A Feb 1 2000, 97(3):1190-1195.
14. Chandrasekar B., Marelli-Berg F.M., Tone M., Bysani S., Prabhu S.D., Murray D.R. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun Jun 25 2004, 319(2):304-311.
15. Murray D.R., Mummidi S., Valente A.J., Yoshida T., Somanna N.K., Delafontaine P., et al. Beta2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo. J Mol Cell Cardiol Jan 2012, 52(1):206-218.
16. Friehs I., Moran A.M., Stamm C., Colan S.D., Takeuchi K., Cao-Danh H., et al. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation Nov 9 1999, 100(19 Suppl.):II187-II193.
17. Moran A.M., Friehs I., Takeuchi K., Stamm C., Hammer P.E., McGowan F.X., et al. Noninvasive serial evaluation of myocardial mechanics in pressure overload hypertrophy of rabbit myocardium. Herz Feb 2003, 28(1):52-62.
18. Friehs I., Margossian R.E., Moran A.M., Cao-Danh H., Moses M.A., del Nido P.J. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol May 2006, 101(3):204-213.
19. Blaauw E., van Nieuwenhoven F.A., Willemsen P., Delhaas T., Prinzen F.W., Snoeckx L.H., et al. Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol Sep 2010, 299(3):H780-H787.
20. Sadoshima J., Izumo S. Mechanotransduction in stretch-induced hypertrophy of cardiac myocytes. J Recept Res 1993, 13(1-4):777-794.
21. Leychenko A., Konorev E., Jijiwa M., Matter M.L. Stretch-induced hypertrophy activates NFkB-mediated VEGF secretion in adult cardiomyocytes. PLoS One 2011, 6(12):e29055.
22. Kubota T., Fang J., Brown R.A., Krueger J.M. Interleukin-18 promotes sleep in rabbits and rats. Am J Physiol Regul Integr Comp Physiol Sep 2001, 281(3):R828-R838.
23. Valente A.J., Clark R.A., Siddesha J.M., Siebenlist U., Chandrasekar B. CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy. J Mol Cell Cardiol Jul 2012, 53(1):113-124.
24. Widmann M.D., Letsou G.V., Phan S., Baldwin J.C., Sumpio B.E. Isolation and characterization of rabbit cardiac endothelial cells: response to cyclic strain and growth factors in vitro. J Surg Res Oct 1992, 53(4):331-334.
25. Kato Z., Jee J., Shikano H., Mishima M., Ohki I., Ohnishi H., et al. The structure and binding mode of interleukin-18. Nat Struct Biol Nov 2003, 10(11):966-971.
26. 2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation. Biochem Biophys Res Commun Apr 18 2003, 303(4):1152-1158.
27. Diwan A., Tran T., Misra A., Mann D.L. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med Mar 2003, 3(2):161-182.
28. Dhalla N.S., Temsah R.M., Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens Jun 2000, 18(6):655-673.
29. Sorescu D., Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail May-Jun 2002, 8(3):132-140.
30. Deschamps A.M., Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res Feb 15 2006, 69(3):666-676.
31. Mishra P.K., Givvimani S., Chavali V., Tyagi S.C. Cardiac matrix: a clue for future therapy. Biochim Biophys Acta Dec 2013, 1832(12):2271-2276.
32. Reddy V.S., Prabhu S.D., Mummidi S., Valente A.J., Venkatesan B., Shanmugam P., et al. Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol Oct 2010, 299(4):H1242-H1254.
33. Kang P.M., Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res Jun 9 2000, 86(11):1107-1113.
34. Olivetti G., Abbi R., Quaini F., Kajstura J., Cheng W., Nitahara J.A., et al. Apoptosis in the failing human heart. N Engl J Med Apr 17 1997, 336(16):1131-1141.
35. Rossig L., Haendeler J., Mallat Z., Hugel B., Freyssinet J.M., Tedgui A., et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol Dec 2000, 36(7):2081-2089.
36. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation Apr 6 2004, 109(13):1594-1602.
37. Abbate A., Kontos M.C., Grizzard J.D., Biondi-Zoccai G.G., Van Tassell B.W., Robati R., et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol May 15 2010, 105(10):1371-1377.
38. Abbate A., Van Tassell B.W., Biondi-Zoccai G., Kontos M.C., Grizzard J.D., Spillman D.W., et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol May 15 2013, 111(10):1394-1400.
39. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J Oct 2011, 162(4):597-605.
40. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013, 4:289.
41. Toldo S., Mezzaroma E., O'Brien L., Marchetti C., Seropian I.M., Voelkel N.F., et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol Apr 1 2014, 306(7):H1025-H1031.